All In Biotech

Drug Trial Radar · NCT07303322

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)

Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 372 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

372

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Jul 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Eurofarma Laboratorios S.A.Industry
Sponsor type
Industry
First posted
Dec 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial designed to evaluate the efficacy and safety of N1087 in women with female pattern hair loss (FPHL). Participants will receive either N1087 or placebo for 24 weeks. The study includes a titration period starting at 0.5 mg and increasing up to 2 mg daily, followed by treatment at the maximum tolerated dose. The primary objective is to assess changes in non-vellus hair density in the target scalp area after 24 weeks. Secondary objectives include changes in terminal hair density, hair thickness, global photographic assessment, quality of life, and participant satisfaction. Safety will be monitored through adverse events, vital signs, and laboratory tests. Approximately 372 participants will be randomized in a 2:1 ratio (N1087 vs. placebo) across about 10 research centers in Brazil.

Conditions

  • Female Pattern Hair Loss
  • Female Pattern Hair Loss, Androgenic Alopecia

Interventions

  • N1087Drug

    N1087 is an oral solution administered in drops. Treatment begins with an 8-week titration period: 0.5 mg/day for 2 weeks, then 1 mg/day, 1.5 mg/day, and up to 2 mg/day every 2 weeks. After titration, participants continue for 16 weeks at the maximum tolerated dose (up to 2 mg/day). Administered orally once daily for a total of 24 weeks.

  • PlaceboDrug

    Placebo administered once daily for 24 weeks, following the same titration schedule as the experimental arm to maintain blinding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in non-vellus hair density (≥0.03 mm diameter) in the target scalp area at Week 24Time frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eurofarma Laboratórios S.A

    Itapevi, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.